<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03713606</url>
  </required_header>
  <id_info>
    <org_study_id>Pan-CHESS1802</org_study_id>
    <nct_id>NCT03713606</nct_id>
  </id_info>
  <brief_title>Serum Biomarkers for Portal Hypertension in Cirrhosis (Pan-CHESS1802)</brief_title>
  <official_title>Serum Biomarkers Associated With Endothelial Dysfunction and Immune Inflammation for Portal Hypertension in Cirrhosis (Pan-CHESS1802)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing YouAn Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Shijitan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xingtai People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing 302 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center diagnostic trial conducted at 6 liver centers in China
      designed to study the correlation between serum biomarkers associated with endothelial
      dysfunction and immune inflammation and hepatic venous pressure gradient in cirrhosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatic venous pressure gradient (HVPG) is the gold standard for assessing portal pressure,
      of which the measurement is invasive and therefore not suitable for routine clinical
      practice. The detection of serum biomarkers is potential for noninvasive diagnosis of portal
      hypertension in cirrhosis. However, many are still in the exploratory phases of testing and
      are not yet ready to enter clinical practice. This study prospectively enrolled participants
      in 6 liver centers (Beijing YouAn Hospital, Shandong Provincial Hospital, Beijing Shijitan
      Hospital, Beijing Friendship Hospital, Xingtai People's Hospital, and 302 Hospital of PLA) in
      China designed to study the correlation between serum biomarkers associated with endothelial
      dysfunction and immune inflammation and HVPG in cirrhosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2018</start_date>
  <completion_date type="Anticipated">February 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between serum biomarkers and HVPG</measure>
    <time_frame>1 day</time_frame>
    <description>Correlation between serum biomarkers and HVPG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between serum biomarkers and HVPG in HBV subgroup</measure>
    <time_frame>1 day</time_frame>
    <description>Correlation between serum biomarkers and HVPG in a subgroup of patients with HBV-related cirrhosis</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Hypertension, Portal</condition>
  <arm_group>
    <arm_group_label>Overall eligible participants</arm_group_label>
    <description>Eligible participants will receive HVPG measurement by catheterization of a hepatic vein with a balloon catheter and run blood tests.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HVPG measurement</intervention_name>
    <description>HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter.</description>
    <arm_group_label>Overall eligible participants</arm_group_label>
    <other_name>Blood test</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cirrhotic portal hypertension
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-75 years;

          -  confirmed cirrhosis based on histologic examination of liver or combined physical,
             laboratory, and radiologic findings, including a nodular surface, a coarse texture,
             and an enlarged caudate lobe of the liver.

        Exclusion Criteria:

          -  prior drug therapy (e.g. Î²-blocker, vasopressin) within two weeks

          -  prior surgeries (e.g. TIPS, partial splenic embolization/ devascularization,
             splenectomy, liver transplantation)

          -  non-sinusoidal portal hypertension &amp; HCC inability to adhere to study procedures

          -  pregnancy or unknown pregnancy status

          -  no informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaolong Qi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaolong Qi, M.D.</last_name>
    <phone>+86 18588602600</phone>
    <email>qixiaolong@vip.163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yanna Liu</last_name>
    <phone>+86 15625076784</phone>
    <email>lauyenna@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>302 Hospital of PLA</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruizhao Qi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ruizhao Qi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Wang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yu Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Shijitan Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fuquan Liu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fuquan Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing YouAn Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huiguo Ding, MD</last_name>
    </contact>
    <investigator>
      <last_name>Huiguo Ding, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Hospital</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunqing Zhang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Chunqing Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xingtai People's Hospital</name>
      <address>
        <city>Xingtai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dengxiang Liu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dengxiang Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology. 2004 Feb;39(2):280-2. Review.</citation>
    <PMID>14767976</PMID>
  </reference>
  <reference>
    <citation>Waidmann O, Brunner F, Herrmann E, Zeuzem S, Piiper A, Kronenberger B. Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis. J Hepatol. 2013 May;58(5):956-61. doi: 10.1016/j.jhep.2013.01.005. Epub 2013 Jan 16.</citation>
    <PMID>23333526</PMID>
  </reference>
  <reference>
    <citation>Buck M, Garcia-Tsao G, Groszmann RJ, Stalling C, Grace ND, Burroughs AK, Patch D, Matloff DS, Clopton P, Chojkier M. Novel inflammatory biomarkers of portal pressure in compensated cirrhosis patients. Hepatology. 2014 Mar;59(3):1052-9. doi: 10.1002/hep.26755. Epub 2014 Jan 29.</citation>
    <PMID>24115225</PMID>
  </reference>
  <reference>
    <citation>Ferlitsch M, Reiberger T, Hoke M, Salzl P, Schwengerer B, Ulbrich G, Payer BA, Trauner M, Peck-Radosavljevic M, Ferlitsch A. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology. 2012 Oct;56(4):1439-47. doi: 10.1002/hep.25806. Epub 2012 Aug 27.</citation>
    <PMID>22532296</PMID>
  </reference>
  <reference>
    <citation>Qi X, Berzigotti A, Cardenas A, Sarin SK. Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension. Lancet Gastroenterol Hepatol. 2018 Oct;3(10):708-719. doi: 10.1016/S2468-1253(18)30232-2. Review.</citation>
    <PMID>30215362</PMID>
  </reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>October 18, 2018</study_first_submitted>
  <study_first_submitted_qc>October 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2018</study_first_posted>
  <last_update_submitted>December 3, 2018</last_update_submitted>
  <last_update_submitted_qc>December 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Xiaolong Qi</investigator_full_name>
    <investigator_title>Director, Hepatic Hemodynamic Lab</investigator_title>
  </responsible_party>
  <keyword>Portal hypertension</keyword>
  <keyword>serum biomarker</keyword>
  <keyword>diagnosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

